Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | USP8 | P40818 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21668232 | 0.89 | P2RY12 (0.51) | P2RY12CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL22772259 | 0.87 | P2RY12 (0.47) | P2RY12CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL21668246 | 0.83 | CYP1A2 (0.53) | CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL19202637 | 0.81 | TNKS (0.51) | CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL21647149 | 0.79 | CYP3A4 (0.63) | CYP1A1CYP1B1CYP1A2USP8 | |
| SCHEMBL26021468 | 0.77 | CYP1A1 (0.44) | P2RY12CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL28848511 | 0.77 | USP8 (0.70) | USP8 | |
| SCHEMBL14696896 | 0.74 | CYP1A1 (0.81) | CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL31632460 | 0.74 | CYP1A1 (0.53) | CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL21647176 | 0.74 | USP8 (0.72) | CYP1A1CYP1B1CYP1A2USP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831821-A1 | COMPOUND FOR TREATING NERVOUS SYSTEM DISEASES AND USE THEREOF | Shaanxi Micot Technology Limited Company (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-20200390755-A1 | COMPOUND FOR TREATING NERVOUS SYSTEM DISEASES AND USE THEREOF | SHAANXI MICOT TECHNOLOGY CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| US-20200390755-A1 | COMPOUND FOR TREATING NERVOUS SYSTEM DISEASES AND USE THEREOF | SHAANXI MICOT TECHNOLOGY CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| WO-2020024977-A1 | COMPOUND FOR TREATING NERVOUS SYSTEM DISEASES AND USE THEREOF | 陕西麦科奥特科技有限公司 | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390755-A1 | COMPOUND FOR TREATING NERVOUS SYSTEM DISEASES AND USE THEREOF | MAPT, PYGB, SLC6A2 | P2RY12 577/4885CYP1A1 283/4885CYP1B1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.